🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07713056
Recruiting Observational

Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy

NCT07713056 · tracked via the Priya Life Science China tracker
Sponsor
Zhongnan Hospital
Phase
Observational
Started
2026-04-01
Last updated
2026-07-20

Condition(s) studied

Pigmentary Glaucoma

Investigational drug(s) / intervention(s)

Ab-interno 120° Trabeculotomy

Ab-interno 120° Trabeculotomy: A minimally invasive glaucoma surgery (MIGS) procedure performed via an ab interno approach, involving a 120-degree incision of the trabecular meshwork to improve aqueous humor outflow.

Study summary

This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.

Eligibility

Sex
ALL
Min age
16 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects; * Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment; * Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements; * Able to complete regular follow-up for at least 6 months postoperatively. Exclusion Criteria: * Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma; * Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment; * Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation; * Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up; * Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhongnan Hospital of Wuhan University Wuhan Hubei Recruiting

More Zhongnan Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07713056 on ClinicalTrials.gov ↗ ← All trials in China